menu
    • menu
    [{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"DHA","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope \/ Not Applicable"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke Department of Medicine","sponsor":"Aker BioMarine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Universit\u00e9 de Sherbrooke Department of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Universit\u00e9 de Sherbrooke Department of Medicine \/ Aker BioMarine","highestDevelopmentStatusID":"4","companyTruncated":"Universit\u00e9 de Sherbrooke Department of Medicine \/ Aker BioMarine"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Hofseth BioCare"},{"orgOrder":0,"company":"Danone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Iron","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Danone","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Danone \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Danone \/ Not Applicable"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"DHA","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lobe Sciences \/ Pentec Health","highestDevelopmentStatusID":"12","companyTruncated":"Lobe Sciences \/ Pentec Health"}]

    Find Clinical Drug Pipeline Developments & Deals for DHA

    Menu

    DHA

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lobe Sciences

                            Canada arrow
                            BePharma
                            Not Confirmed

                            Lobe Sciences

                            Canada arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DHA

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Pentec Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™

                            Details : Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD...

                            Product Name : Altemia

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 17, 2023

                            Lead Product(s) : DHA

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Pentec Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Danone

                            France arrow
                            BePharma
                            Not Confirmed

                            Danone

                            France arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron,DHA

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Infant Formula Update: June 17, 2022

                            Details : Aptamil (Iron) First Infant Milk Stage 1(This infant formula is appropriate for most infants and meets U.S. nutrient requirements, but it may not be suitable for infants born prematurely, or with a low birth weight.

                            Product Name : Aptamil

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 17, 2022

                            Lead Product(s) : Iron,DHA

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Catalent Pharma Solutions

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Catalent Pharma Solutions

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DHA,Icosapent Ethyl

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Hofseth BioCare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Hofseth BioCare Announces Global Innovation Partnership with Catalent to Develop Delayed-Release Formulation o...

                            Details : The partnership will see Catalent use its proprietary OptiGel® DR technology to encapsulate OmeGo (docosahexaenoic acid), HBC’s unique fish oil derived from sustainable, traceable, and fresh Norwegian Atlantic salmon.

                            Product Name : OmeGo

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 12, 2021

                            Lead Product(s) : DHA,Icosapent Ethyl

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Hofseth BioCare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Université de Sherbrooke Department of Medicine

                            Country arrow
                            BePharma
                            Not Confirmed

                            Université de Sherbrooke Department of Medicine

                            Country arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl,DHA

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Aker BioMarine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aker BioMarine Enters Into Research Collaboration for Alzheimer’s

                            Details : Université de Sherbrooke in Canada will test if LYSOVETA, Aker BioMarine’s new delivery platform based on LPC-bound EPA/DHA from krill, is more effective in increasing the concentration of DHA in the brain and improving cognition.

                            Product Name : Lysoveta

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 15, 2021

                            Lead Product(s) : Icosapent Ethyl,DHA

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Aker BioMarine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Retrotope

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Retrotope

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DHA

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Retrotope Starts IND Enabling Studies for its Second D-PUFA Drug Candidate, Targeting the Treatment of AMD and...

                            Details : Comapny's first D-PUFA drug candidate in development, RT001, has shown robust safety in over 50 patient years of oral dosing, and we expect RT011 to have a similar safety profile.

                            Product Name : RT011

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 21, 2020

                            Lead Product(s) : DHA

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth